INCY vs ABBV: Incyte vs AbbVie Stock Comparison: AI Score, Valuation, Performance and Upside
Incyte is a focused JAK inhibitor biotech with Jakafi and Opzelura as its primary revenue drivers and an oncology-heavy pipeline, while AbbVie is a large-cap diversified biopharma managing Humira's biosimilar transition with Skyrizi, Rinvoq, and Botox. AbbVie is the safer, more diversified biopharma; Incyte is the smaller focused JAK inhibitor bet.
INCY vs ABBV is a focused JAK inhibitor biotech versus a diversified large-cap biopharma successfully managing the world's largest drug franchise biosimilar transition — Incyte wins if Opzelura and oncology pipeline succeed; AbbVie wins if Skyrizi/Rinvoq fully offset Humira erosion.
INCY holds the edge across 3 of 5 key metrics in this comparison. INCY leads on both 1-year return (+28.50%) and forward P/E quality (13.91x vs 15.79x for ABBV), a relatively favorable combination of momentum and valuation. INCY leads on both revenue growth (37.70%) and operating margin (41.90%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+7.85%) than for INCY (+2.22%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want focused JAK inhibitor exposure with Opzelura growth in atopic dermatitis
- value Jakafi's standard-of-care position in myelofibrosis as a durable revenue base
- prefer a smaller, more focused biotech with clear near-term growth drivers
- are comfortable with binary pipeline clinical risk from oncology candidates
- prefer a large-cap biopharma with diversified revenue across immunology, aesthetics, and oncology
- value the Skyrizi and Rinvoq growth trajectory that is offsetting Humira biosimilar erosion
- want dividend income from a profitable pharmaceutical company with durable cash flows
- are comfortable with Humira biosimilar pressure as an already-known headwind with declining impact
| Metric | INCY | ABBV |
|---|---|---|
| AI scorei | 41.1 | 61.2 |
| AI ranki | #784 | #215 |
| Latest closei | $113.27 | $283.40 |
| 1M returni | -6.96% | +7.74% |
| 3M returni | -2.90% | +11.40% |
| 6M returni | +18.83% | +35.60% |
| 1Y returni | +28.50% | +25.28% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | INCY | ABBV |
|---|---|---|
| 1Y ago | $12.97K (+29.7%) started 2025-10-16 | $12.49K (+24.9%) started 2025-10-16 |
| 5Y ago | $17.54K (+75.4%) started 2021-10-18 | $34.69K (+246.9%) started 2021-10-18 |
| 10Y ago | $13.06K (+30.6%) started 2016-10-17 | $104.43K (+944.3%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | INCY | ABBV |
|---|---|---|
| Market capi | $25.21B | $454.36B |
| Trailing P/Ei | 15.84 | 72.43 |
| Forward P/Ei | 13.91 | 15.79 |
| Price/Salesi | N/A | 5.85 |
| EV/Revenuei | 3.56 | 8.06 |
| Analyst targeti | $127.13 | $277.31 |
| Target upsidei | +2.22% | +7.85% |
| Metric | INCY | ABBV |
|---|---|---|
| Revenue growthi | 37.70% | 10.20% |
| Earnings growthi | 37.70% | 290.40% |
| EPS growthi | +37.70% | +290.40% |
| FCF margini | +20.29% | +26.20% |
| Operating margini | 41.90% | 40.03% |
| Profit margini | 27.71% | 9.80% |
| ROIC proxyi | 30.67% | 6225.00% |
| Return on equityi | 30.67% | 6225.00% |
| Dividend yieldi | N/A | 2.69% |
| Payout ratioi | 0.00% | 190.40% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.77 | 0.28 |
| Debt/equityi | 0.60 | 4789.60 |
| Current ratioi | 4.59 | 0.81 |
| Quick ratioi | 4.31 | 0.49 |
Over the past year, INCY and ABBV have moved weakly in the same direction (correlation of 0.34), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | INCY | ABBV |
|---|---|---|---|
| 1Y | Growthi | +29.73% | +24.92% |
| CAGRi | +29.79% | +24.97% | |
| Volatilityi | 33.35% | 25.72% | |
| Sharpe ratioi | 0.81 | 0.82 | |
| Sortino ratioi | 1.29 | 1.24 | |
| Max drawdowni | 18.33% | 16.46% | |
| Current drawdowni | 12.82% | 0.03% | |
| Avg drawdowni | 7.38% | 5.19% | |
| Ulcer Indexi | 8.92% | 6.66% | |
| Max daily dropi | 8.24% | 5.20% | |
| Max wkly dropi | 8.91% | 8.49% | |
| 5Y | Growthi | +75.39% | +201.12% |
| CAGRi | +11.91% | +24.70% | |
| Volatilityi | 30.05% | 23.42% | |
| Sharpe ratioi | 0.38 | 0.87 | |
| Sortino ratioi | 0.55 | 1.22 | |
| Max drawdowni | 40.50% | 21.92% | |
| Current drawdowni | 12.82% | 0.03% | |
| Avg drawdowni | 15.83% | 8.01% | |
| Ulcer Indexi | 19.49% | 9.97% | |
| Max daily dropi | 8.62% | 12.57% | |
| Max wkly dropi | 12.82% | 17.30% | |
| 10Y | Growthi | +30.65% | +576.86% |
| CAGRi | +2.71% | +21.08% | |
| Volatilityi | 34.16% | 26.04% | |
| Sharpe ratioi | 0.12 | 0.70 | |
| Sortino ratioi | 0.17 | 0.97 | |
| Max drawdowni | 66.47% | 45.09% | |
| Current drawdowni | 25.80% | 0.03% | |
| Avg drawdowni | 44.60% | 11.47% | |
| Ulcer Indexi | 47.05% | 15.55% | |
| Max daily dropi | 22.93% | 16.25% | |
| Max wkly dropi | 23.17% | 19.39% |
| Category | INCY | ABBV |
|---|---|---|
| Company | Incyte Corporation | AbbVie Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Core business | Biopharmaceutical company specializing in JAK inhibitor drugs, with Jakafi (ruxolitinib) for myelofibrosis and polycythemia vera, and Opzelura (ruxolitinib cream) for atopic dermatitis. Incyte's pipeline focuses on oncology and inflammatory diseases. | Diversified biopharmaceutical company with Skyrizi and Rinvoq (immunology), Humira (biosimilar competition began 2023), Botox (Allergan acquisition), and oncology. AbbVie has successfully pivoted from Humira dependence to Skyrizi/Rinvoq growth. |
| Investor focus | Opzelura (ruxolitinib cream) growth for atopic dermatitis, Jakafi lifecycle management, oncology pipeline advancement, and pipeline success in solid tumors. | Skyrizi and Rinvoq combined peak revenue potential, Humira biosimilar erosion pace, Botox and aesthetics durability, and pipeline advancement in neuroscience and oncology. |
- Jakafi is the standard of care for myelofibrosis with minimal near-term generic competition
- Opzelura's topical JAK inhibitor penetration in atopic dermatitis is growing rapidly as an alternative to systemic biologics
- Strong balance sheet with no debt provides flexibility for business development and R&D investment
- Skyrizi and Rinvoq combined are growing faster than Humira's biosimilar erosion, validating AbbVie's immunology transition
- Allergan Aesthetics (Botox, Juvederm, CoolSculpting) provides diversified revenue in the aesthetics market
- Deep immunology franchise expertise creates a durable platform for future drug development
- Opzelura faces competition from Pfizer's Cibinqo (JAK inhibitor cream) and other topical treatments for atopic dermatitis
- Jakafi patent expiration creates long-term biosimilar headwind that Incyte must offset with pipeline success
- Binary clinical read-out risk from oncology pipeline candidates
- Skyrizi and Rinvoq pricing pressure if biosimilar competition develops in IL-23 and JAK inhibitor markets
- Humira biosimilar erosion, while partly offset by Skyrizi/Rinvoq, still weighs on net revenue
- Neuroscience pipeline (psychiatric drugs) has a binary risk profile as trials proceed
Compare more than two at a time
This page is a fixed writeup on INCY and ABBV. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside INCY and ABBV, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.